Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2008
09/04/2008WO2008104532A1 Topical composition comprising fluocinolone acetonide for use in depigmentation of the skin
09/04/2008WO2008104524A1 Thiadiazole derivatives, inhibitors of stearoyl-coa desaturase
09/04/2008WO2008104512A2 Novel polymorphs of aprepitant and processes for preparation
09/04/2008WO2008104475A1 Isoquinolinopyrrolopyridinones active as kinase inhibitors
09/04/2008WO2008104474A1 Diaminopyrimidines
09/04/2008WO2008104472A1 2, 4 -diaminopyrimidine derivatives and their use as p2x antagonists or as prodrugs thereof
09/04/2008WO2008104387A1 Use of inhibitors of the degradation of p27, in particular argyrin and derivatives thereof, for the treatment of proliferative diseases
09/04/2008WO2008104386A2 Method for the treatment of amyloidoses
09/04/2008WO2008104342A1 Pharmaceutical preparation for the alleviation of endometriosis
09/04/2008WO2008104306A2 Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
09/04/2008WO2008104279A1 Imidazo[1,2-a]azines and their use as pharmaceuticals
09/04/2008WO2008104278A1 Imidazo[1,2-a] pyridines and their use as pharmaceuticals
09/04/2008WO2008104239A1 Composition useful for the treatment of type 2 diabetes
09/04/2008WO2008104215A1 Oil-in-water emulsions ii which are stabilized by their active ingredient
09/04/2008WO2008104203A2 18f fluoro-benzoyl labelled biological active coumpounds as diagnositic imaging agents as well as benzotriazol-1-yloxy-benzoyl, 2,5-dioxo-pyrrolidin-1-yloxy) benzoyl and trimethylammonio-benzoyl precursers
09/04/2008WO2008104187A1 Pharmaceutical composition comprising glibenclamide coenzyme q10 and vitamins for the treatment of diabetes
09/04/2008WO2008104186A1 Pharmaceutical composition comprising a steroid and vitamins
09/04/2008WO2008104175A2 Novel phosphodiesterase inhibitors
09/04/2008WO2008104161A1 ß-CARBOLINES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
09/04/2008WO2008104124A1 Screening method of combination pharmaceuticals, pharmaceuticals obtained by the method and uses thereof
09/04/2008WO2008104084A1 Linoleoyl-containing phospholipids and methods for their use
09/04/2008WO2008104077A1 Small molecule inhibitors of protein arginine methyltransferases (prmts)
09/04/2008WO2008104055A1 Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists
09/04/2008WO2008090200A3 2- piperazin-1-yl-3h-imidazo[4,5-b]pyridine derivatives
09/04/2008WO2008088864A9 Matrix metalloproteinase-9-related methods
09/04/2008WO2008086804A3 Use of i) a polyglycol and n) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
09/04/2008WO2008086678A3 The medical use of levo-phencynonate as neuroprotective agent
09/04/2008WO2008086462A3 AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF β-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS
09/04/2008WO2008084067A3 Pharmaceutically active dihydrobenzofurane-substituted benzimidazole derivatives
09/04/2008WO2008083238A3 Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
09/04/2008WO2008081104A3 Conglomerates of tenatoprazole potassium salts
09/04/2008WO2008080965A3 Hiv inhibiting 5,6-substituted pyrimidines
09/04/2008WO2008079814A3 Mapk/erk kinase inhibitors
09/04/2008WO2008074834A3 Isoquinolinecarboxamides as inhibitors of stearoyl-coa desaturase (scd)
09/04/2008WO2008070937A3 Imidazo [1, 2-a] pyrrolo [3, 2-c] pyridine compounds useful as pestivirus inhibitors
09/04/2008WO2008063301A3 Pharmaceutical compositions
09/04/2008WO2008063114A9 Amino- imidazolones and their use as medicament for treating cognitive impairment alzheimer disease, neurodegeneration and dementia
09/04/2008WO2008062253A3 Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
09/04/2008WO2008061966A8 New use of flibanserin
09/04/2008WO2008060622A3 Improved methods and compositions for wound healing
09/04/2008WO2008058225A3 Methods and compositions for treating cancer using bcl-2 antisense oligomers, tyrosine kinase inhibitors, and chemotherapeutic agents
09/04/2008WO2008057503A3 Compositions including triciribine and taxanes and methods of use thereof
09/04/2008WO2008055666A8 Carbamate, thiocarbamate or carbamide comprising a biomolecular moiety
09/04/2008WO2008054956A3 Kinase inhibitors
09/04/2008WO2008054693A9 Uses of tetrahydrobiopterin and derivatives thereof
09/04/2008WO2008048205A3 Method for delivering hydrophobic drugs via nanocrystal formulations
09/04/2008WO2008047229A3 Biaryl ether urea compounds
09/04/2008WO2008042898A9 Ketoconazole enantiomer in humans
09/04/2008WO2008042755A3 Inhibitors of cognitive decline
09/04/2008WO2008040361A3 Use of a combination of hypothermia inducing drugs
09/04/2008WO2008033746A3 Tyrosine kinase inhibitors containing a zinc binding moiety
09/04/2008WO2008029264A3 Method of treating bone cancer
09/04/2008WO2008019996A3 Formulations of flibanserin and method for manufacturing the same
09/04/2008WO2008019063A3 Defoliant composition and method
09/04/2008WO2008014393A3 Non-invasive in-vivo imaging of mechanoreceptors in skin using confocal microscopy
09/04/2008WO2008012666A3 Treatment and prevention mucositis by anthocyanidin derivatives
09/04/2008WO2008011381A3 Treatment of pain through expression of opioid receptors
09/04/2008WO2008011364A3 Quercetin-containing compositions
09/04/2008WO2008008215A3 Method for enhancing pdt efficacy using a tyrosine kinase inhibitor
09/04/2008WO2008005783A3 Treatment of non- infectious inflammatory vulvovaginitis with a bioadhesive clindamycin composition
09/04/2008WO2008000513A3 Peptide compounds for the treatment of hyperexcitability disorders and diseases associated with ion channel dysfunction
09/04/2008WO2008000429A3 Polymers with antimicrobial activity containing quaternary ammonium groups
09/04/2008WO2007149523A3 Hexahydro-isoalpha acid based protein kinase modulation cancer treatment
09/04/2008WO2007149508A3 Non-competitive nmda receptor antagonists
09/04/2008WO2007144195A3 Pharmaceutical composition with synergistic anticonvulsant effect
09/04/2008WO2007142967A3 Alcohol-containing antimicrobial compositions having improved efficacy
09/04/2008WO2007139826A3 Method for elevating prolactin in mammals
09/04/2008WO2007132293A3 Once-daily administration of central nervous system drugs
09/04/2008WO2007126988A3 Selective androgen receptor modulators and methods of use thereof
09/04/2008WO2007121924A3 Bisadenosine compounds as adenosine a2a receptor agonists
09/04/2008WO2007117544A3 Carnitine conjugates of adamantanamines and neramexane derivatives as duel prodrugs for various uses
09/04/2008WO2007109582A3 Method of treating pulmonary edema or pulmonary inflammation
09/04/2008WO2007109312A3 Disease modifying anti-arthritic activity of 2-methoxyestradiol
09/04/2008WO2007103770A3 Compositions and methods for analyzing renal cancer
09/04/2008WO2007100624A3 Hydroxylamines and derivatives for treatment of inflammatory conditions of the liver
09/04/2008WO2007099302A8 Methods of maintaining oral health in animals using morpholine derivatives
09/04/2008WO2007098142A3 Oxazole ketones as modulators of fatty acid amide hydrolase
09/04/2008WO2007092414A8 Use of phosphatases to treat tumors overexpressing n-cor
09/04/2008WO2007071861A8 Compositions including at least one retinoid compound and at least one anti-irritant compound and uses thereof
09/04/2008WO2007054776A3 Stilbene like compounds as novel hdac inhibitors
09/04/2008US20080216184 Modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms
09/04/2008US20080215122 Plasmonic engineering of singlet oxygen and/or superoxide generation
09/04/2008US20080215032 Minimizing Metal Toxicity During Electroporation Enhanced Delivery of Polynucleotides
09/04/2008US20080214870 Method of Preparing Amine Stereoisomers
09/04/2008US20080214853 Method for monitoring blood flow and metabolic uptake in tissue with radiolabeled alkanoic acid
09/04/2008US20080214851 Synthesis of labeled fatty acid analogs for use in tomography
09/04/2008US20080214849 for transporting drugs or as gene transport vehicles, as solubilizers for drugs of low solubility in water, and themselves as active ingredients against diseases such as cancer or leishmaniosis; (Z)-6-octadecenyl-1-phospho-N,N,N-trimethylpropylammonium
09/04/2008US20080214820 The desired characteristics of chiral compounds helps reduce the toxicity of compound; to treat mood disorders, depression; pain, neurodegenerative disorders, sexual disorders, drug abuse etc.
09/04/2008US20080214812 Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition
09/04/2008US20080214802 Treating sepsis, septicemia and septic shock
09/04/2008US20080214677 Chitosan-Silicon Dioxide Coprecipitate and Use as Excipient in Solid Dosage Forms
09/04/2008US20080214676 N-(1-cyanocyclopropyl)-4,4-difluoro-2(S)-[2,2,2-trifluoro-1(S)-(4-fluorophenyl)ethylamino)octamide; rheumatoid arthritis, multiple sclerosis, myasthenia gravis, psoriasis, pemphigus vulgaris, Graves' disease, myasthenia gravis, lupus, asthma, pain, atherosclerosis; cathepsins B, K, L, F, and S inhibitors
09/04/2008US20080214675 Hydroxybenzoic Acid Amides and the Use Thereof For Masking Bitter Taste
09/04/2008US20080214674 Acylhydrazone derivatives and the use thereof in the inhibition, regulation and/or modulation of kinase signal transduction
09/04/2008US20080214673 e.g. Furan-3-carboxylic acid [(1R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-amide; metabotropic glutamate receptors modulator/antagonist;anxiolytic agent, antidepressant; amidation of amine-compounds
09/04/2008US20080214672 Treatment of Asthma with Aryl Sulfonamides
09/04/2008US20080214671 Administering dicarbonic acids as metastasis inhibitors and agents enhancing chemotherapeutic activity of anti-tumor agents; in combination with cisplatin at the minimum doses, completely inhibiting the metastasis process in experimental B-16 melanoma
09/04/2008US20080214670 Therapeutic Malonic Acid/Acetic Acid C60 Tri-Adducts of Buckminsterfullerene and Methods Related Thereto
09/04/2008US20080214669 Hydroxycinnamic acid, a methoxycinnamic acid, dissolved in a compound having hydroxy groups; lightening skin
09/04/2008US20080214668 Use of retinoids to treat high blood pressure and other cardiovascular disease